title: [Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials].
authors.affiliation: Centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France. Electronic address: n-penel@o-lambret.fr.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Penel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D003841:Deoxycytidine; C000594389:atezolizumab; C111217:vinflunine; D014747:Vinblastine; D016190:Carboplatin; D002945:Cisplatin; D000093542:Gemcitabine